BioSpace News Archive

Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44th Annual Global Healthcare Conference at 2:20 p.m. ET on Wednesday, June 14, 2023.

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, announced that it will release financial results for the third quarter of fiscal year 2023 ended March 31, 2023, before the market open on Monday, June 12, 2023.

Science 37 Holdings, Inc., the industry-leading Metasite™, announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan.

Pursuant to the signing of a Letter of Intent in December 2022, Asep Medical Holdings Inc. is delighted to announce it has signed a definitive agreement for a joint venture with Bahrain-based international investment consultancy firm, Seaspring W.L.L., to advance regulatory approval and commercialization of the Company’s sepsis diagnosis technology in the Kingdom of Bahrain and the Middle East and North Africa.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that positive results from the global Phase III COMMODORE 1 and 2 studies, evaluating the efficacy and safety of crovalimab, an investigational, novel anti-C5 recycling monoclonal antibody, compared to eculizumab.

Shionogi & Co., Ltd. today announced the first participant has been enrolled in Japan in its global Phase 3 study, Stopping COVID-19 pRogression with early Protease InhibitOr treatment – Post Exposure Prophylaxis (SCORPIO-PEP).

Rallybio Corporation (Nasdaq: RLYB) today announced that results from the RLYB212 Phase 1b proof-of-concept study will be presented at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 12 scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 46th European Cystic Fibrosis Conference held June 7-10, 2023, in Vienna, Austria.

Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that it has received FDA approval for its generic version of Precedex®, Dexmedetomidine Hydrochloride Injection 4mcg/ml in 50mL and 100mL, and plans to launch in the very near future.

Sumitomo Pharma Oncology, Inc., today presented updated preliminary data from the ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis (MF) previously treated with or ineligible for JAK inhibitor therapy.